國家衛生研究院 NHRI:Item 3990099045/15088

NHRI > National Institute of Infectious Diseases and Vaccinology > Ching-Len Liao > Periodical Articles > Item 3990099045/15088

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15088

Title:	Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement
Authors:	Yen, LC;Chen, HW;Ho, CL;Lin, CC;Lin, YL;Yang, QW;Chiu, KC;Lien, SP;Lin, RJ;Liao, CL
Contributors:	National Mosquito-Borne Diseases Control Research Center;National Institute of Infectious Diseases and Vaccinology
Abstract:	BackgroundFlavivirus causes many serious public health problems worldwide. However, licensed DENV vaccine has restrictions on its use, and there is currently no approved ZIKV vaccine. Development of a potent and safe flavivirus vaccine is urgently needed. As a previous study revealed the epitope, RCPTQGE, located on the bc loop in the E protein domain II of DENV, in this study, we rationally designed and synthesized a series of peptides based on the sequence of JEV epitope RCPTTGE and DENV/ZIKV epitope RCPTQGE.MethodsImmune sera were generated by immunization with the peptides which were synthesized by using five copies of RCPTTGE or RCPTQGE and named as JEV-NTE and DV/ZV-NTE. Immunogenicity and neutralizing abilities of JEV-NTE or DV/ZV-NTE-immune sera against flavivirus were evaluated by ELISA and neutralization tests, respectively. Protective efficacy in vivo were determined by passive transfer the immune sera into JEV-infected ICR or DENV- and ZIKV-challenged AG129 mice. In vitro and in vivo ADE assays were used to examine whether JEV-NTE or DV/ZV-NTE-immune sera would induce ADE.ResultsPassive immunization with JEV-NTE-immunized sera or DV/ZV-NTE-immunized sera could increase the survival rate or prolong the survival time in JEV-challenged ICR mice and reduce the viremia levels significantly in DENV- or ZIKV-infected AG129 mice. Furthermore, neither JEV -NTE- nor DV/ZV-NTE-immune sera induced antibody-dependent enhancement (ADE) as compared with the control mAb 4G2 both in vitro and in vivo.ConclusionsWe showed for the first time that novel bc loop epitope RCPTQGE located on the amino acids 73 to 79 of DENV/ZIKV E protein could elicit cross-neutralizing antibodies and reduced the viremia level in DENV- and ZIKV-challenged AG129 mice. Our results highlighted that the bc loop epitope could be a promising target for flavivirus vaccine development.
Date:	2023-06-14
Relation:	Journal of Biomedical Science. 2023 Jun 14;30:Article number 41.
Link to:	http://dx.doi.org/10.1186/s12929-023-00938-y
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1021-7770&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:001007868300001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85161863356
Appears in Collections:	[Ching-Len Liao] Periodical Articles [Others] Periodical Articles

Files in This Item:

File	Description	Size	Format
ISI001007868300001.pdf		2312Kb	Adobe PDF	141	View/Open

Loading...